Delegation of China pharmaceutical promotion association visited German Association of research pharmaceutical enterprises, Bayer company and German Federation of industry (series report V of visiting Europe)

Source: China pharmaceutical innovation promotion association July 6, 2017 On July 3, song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as China pharmaceutical promotion association), led a delegation of China pharmaceutical promotion association to visit the German research Pharmaceutical Enterprises Association (VFA), Bayer company and BDI in Berlin, Germany and other representative enterprises and industry organizations in the German pharmaceutical industry In the morning, the delegation visited the German Association of research pharmaceutical enterprises (VFA) Harald Zimmer, director of VFA International Department, Tina Taube, project director of patient access and global reimbursement system, and Jan bungenstock, senior manager of reimbursement system and Strategy Department received the delegation At the meeting with VFA representatives, Harald Zimmer, director of VFA International Department, introduced the association to the delegation VFA is the industry association of German research pharmaceutical companies and the governing unit of IFPMA The association has 45 leading research pharmaceutical enterprises in Germany Its member enterprises have more than 100 subsidiaries and subordinate institutions, about 80000 employees in Germany, more than 18000 R & D personnel in Germany, and an average annual investment of 6 billion euros in R & D funds Its products cover more than two-thirds of the German pharmaceutical market, occupying an advanced position in the global pharmaceutical R & D field, representing one German high-tech industry with global competitiveness Song Ruilin, executive chairman, introduced the members of the delegation to VFA representatives, and said that China pharmaceutical promotion association, like VFA, is an innovative pharmaceutical association, committed to promoting the innovation and development of China's pharmaceutical industry At present, China is the second largest pharmaceutical market in the world, which is both an opportunity and a challenge for developed countries China Council for the promotion of drugs hopes to further increase exchanges and cooperation with VFA to jointly study the current situation and challenges of the pharmaceutical industry in China and Germany, establish more contacts and cooperation, deepen policy exchanges of the medical and health system, and promote extensive cooperation between China and Germany in the field of pharmaceutical innovation Ms Tina Taube, project leader of VFA patient access and global reimbursement system, introduced the German drug reimbursement system and its impact on German innovative drugs Subsequently, the delegation visited Bayer's headquarters in Germany and held talks with LARS br ü Ning, head of Bayer's international market access, faten Gaber, head of international drug health policy and other management During the group photo meeting with representatives of Bayer company in Germany, larsbr ü Ning, head of Bayer market access, introduced the situation of German pharmaceutical industry in detail to the delegation, and conducted in-depth exchanges on German pharmaceutical innovation, medical insurance reimbursement policy and cooperation between China and Germany Larsbr ü Ning mentioned that at present, the Chinese government has introduced many encouraging measures, including reducing the time of drug review and approval, reducing the approval process, accepting the international multi center clinic, patent link, data protection and accelerating the reimbursement of innovative drugs Then the medical situation in Germany is introduced in detail Germany is a country with high social welfare The government bears 90% of the medical insurance and only 10% of the medical insurance is personal, which greatly improves the access of patients to medication Since the implementation of the pharmaceutical product market reform act (amnog) in 2011, compared with the market access time in France for about one year, Germany's waiting period for the access and listing of innovative drugs is zero, once approved, they can be listed immediately; if the products of enterprises want to enter the medical insurance catalog, they will go through a one-year drug evaluation and price negotiation process, during which enterprises can make independent pricing If the price negotiation fails to reach an agreement, the enterprise can apply for arbitration, or choose to withdraw from the German market; the price of medical insurance will determine the reimbursement proportion according to the level of benefits, so the enterprise needs to prove the benefits of its products through effective data as much as possible Song Ruilin, executive chairman of CFDA, said that CFDA would like to learn more about the development process and policy environment of international excellent enterprises China and Germany have maintained good national relations China's pharmaceutical industry also respects Germany's pharmaceutical industry and hopes to establish long-term and friendly cooperation with Germany's pharmaceutical industry Different policy research and analysis should be carried out for the policy environment of different countries, and internal R & D strategies and external regulatory strategies should be formulated to adapt to the policies of different governments In the afternoon, the delegation visited the Federation of German Industries (BDI) Friedolin Strack, director of BDI's International Department, general manager of APA, Patricia schetelig, deputy director of BDI's international marketing department, Ferdinand Schaff, senior manager of APA's China Affairs Office, and Diana Peters, representative of GHP under BDI, held talks with the delegation Meeting with BDI representatives: Song Ruilin, executive chairman, and friedolin Strack, director of BDI International Department and general manager of APA Founded in 1952 in Berlin, Germany, BDI is a social organization representing the interests of many industrial sectors and industrial service sectors in Germany Its purpose is to safeguard the interests of industrial industries, promote industrial development in Germany and enhance international competitiveness It plays an important role in participating in government policy-making, promoting industry development and regulation, and improving the global competitiveness of German industry There are 36 Association members, providing services for more than 100000 member enterprises and 8 million employees German healthcare partnership (GHP) is a medical association under the German Federation of industry Both sides discussed in-depth the role of German industry associations in the formulation of relevant policies and the innovation environment in the field of medicine and health; both sides agreed that only by strengthening exchanges and understanding between them can we really promote industrial cooperation between China and Germany and achieve a good win-win situation The two sides look forward to continuing to maintain cooperation and contribute to the cooperation between enterprises of the two countries, especially in the field of medicine!